Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma

27 Jul 2023

Abstract excerpt

Despite substantial recent advances in treatment, multiple myeloma (MM) remains an incurable disease, with a shortage of treatment options for patients with high-risk disease, warranting the need for novel therapeutic targets and treatment approaches. Threonine and tyrosine kinase (TTK), also known as monopolar spindle 1 (MPS1), is a kinase essential for the mitotic spindle checkpoint whose expression correlates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Microtubule and mitosis dynamics
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37496433
DOI: 10.3324/haematol.2023.282838

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myelomaPMID 37496433Read ↗

Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic DrugsSemantic proximity Read ↗

High WEE1 expression is independently linked to poor survival in multiple myelomaSemantic proximity Read ↗

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancerSemantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

Development of MPS1 Inhibitors: Recent Advances and PerspectivesSemantic proximity Read ↗

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.Semantic proximity Read ↗

TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instabilitySemantic proximity Read ↗

Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 KinaseSemantic proximity Read ↗

Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair ProteinsSemantic proximity Read ↗

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair InhibitorsSemantic proximity Read ↗

Therapeutic Potential of PRMT1 as a Critical Survival Dependency Target in Multiple MyelomaSemantic proximity Read ↗

Kinome expression profiling to target new therapeutic avenues in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.